Effector Therapeutics Inc. (EFTR)
OTC PINK OTC PINK Primary Summary
Effector Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RB Robert Burns HC Wainwright & Co. | -2,897.55 | $29,389.81 | - | $29,389.81 | 100% |
Effector Therapeutics Inc. (EFTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Effector Therapeutics Inc. ever had a stock split?
Effector Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Davide Ruggero CEO | OTC PINK Exchange | 28202V108 CUSIP |
| US Country | 14 Employees | - Last Dividend | 12 Jan 2024 Last Split | 26 Aug 2021 IPO Date |
Overview
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's innovative approach aims to discover and develop therapeutic options that target the processes involved in protein production within cancer cells, potentially halting or slowing their growth and proliferation. Founded in 2012, eFFECTOR Therapeutics has swiftly advanced to the clinical stages, demonstrating its commitment to addressing unmet medical needs through novel science. Headquartered in Solana Beach, California, the company has forged a substantial research collaboration and license agreement with Pfizer Inc., further bolstering its capability to develop cutting-edge oncology treatments.
Products and Services
- Tomivosertib
- Zotatifin
An oral small-molecule inhibitor of MNK, Tomivosertib is at the forefront of eFFECTOR Therapeutic’s pipeline. Currently in a phase 2b clinical trial, this candidate represents the company’s aspiration to provide a new avenue of treatment for patients suffering from metastatic non-small cell lung cancer. By targeting the mitogen-activated protein kinase-interacting kinases (MNK), Tomivosertib aims to interfere with cancer cell growth and survival mechanisms, potentially improving patient outcomes in a disease with limited therapeutic options.
At the cutting edge of translational control mechanisms in cancer, Zotatifin is a small molecule inhibitor targeting the eukaryotic initiation factor 4A (eIF4E). Engaged in Phase 1/2 clinical trials, Zotatifin’s scope extends to treating patients with solid tumors, embodying eFFECTOR's commitment to tackling a broad spectrum of cancer types. The drug has also completed a Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib, aimed at treating patients with ER+ breast cancer. This pivotal study showcases the potential of combining Zotatifin with other therapeutic agents to possibly enhance treatment efficacy against complex cancers.
